REM:JSERemgro Limited Analysis
Data as of 2026-06-28 - not real-time
ZAC 19,329.00
Latest Price
3/10Risk
Risk Level: Low
Executive Summary
Remgro is trading just above its short‑term moving averages, with the 20‑day and 50‑day SMAs providing a modest support cushion. The MACD histogram remains firmly positive and the signal line is bullish, while the RSI sits in the mid‑range, indicating no immediate overbought pressure. Fundamentally, the company’s price‑to‑earnings ratio sits far below the sector average, and its price‑to‑book is under one, suggesting a strong value tilt.
The dividend yield sits comfortably in the low‑single digits with an exceptionally low payout ratio, pointing to ample earnings coverage. Volatility over the past month is moderate, and beta is markedly low, underscoring the stock’s defensive character. Combined with a DCF‑derived upside of roughly 17% and an “Extreme Greed” sentiment reading, the risk‑adjusted profile appears attractive for patient investors.
The dividend yield sits comfortably in the low‑single digits with an exceptionally low payout ratio, pointing to ample earnings coverage. Volatility over the past month is moderate, and beta is markedly low, underscoring the stock’s defensive character. Combined with a DCF‑derived upside of roughly 17% and an “Extreme Greed” sentiment reading, the risk‑adjusted profile appears attractive for patient investors.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD but neutral price trend
- Price slightly above short‑term SMAs
- Stable volume with low beta
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF upside indicating price undervaluation
- Strong dividend coverage and low payout
- Defensive risk profile with low volatility
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Sustained value metrics relative to industry peers
- Robust cash generation and manageable debt
- Long‑term defensive positioning in a diversified investment portfolio
Key Metrics & Analysis
Financial Health
Revenue Growth2.80%
Profit Margin9.21%
P/E Ratio0.7
ROE3.67%
ROA1.34%
Debt/Equity4.05
P/B Ratio0.9
Op. Cash FlowZAC9.7B
Free Cash FlowZAC739.6M
Industry P/E16.9
Technical Analysis
TrendNeutral
RSI56.2
SupportZAC 18,202.00
ResistanceZAC 19,686.00
MA 20ZAC 18,987.10
MA 50ZAC 19,147.28
MA 200ZAC 18,278.58
MACDBullish
VolumeStable
Fear & Greed Index88.55
Valuation
Fair ValueZAC 3,886.15
Target PriceZAC 22,584.00
Upside/Downside16.84%
GradeUndervalued
TypeValue
Dividend Yield2.18%
Risk Assessment
Beta0.16
Volatility12.92%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.